You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

LIBERVANT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Libervant patents expire, and when can generic versions of Libervant launch?

Libervant is a drug marketed by Aquestive and is included in one NDA. There is one patent protecting this drug.

This drug has twenty patent family members in eight countries.

The generic ingredient in LIBERVANT is diazepam. There are eight drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the diazepam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Libervant

A generic version of LIBERVANT was approved as diazepam by MYLAN on September 4th, 1985.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LIBERVANT?
  • What are the global sales for LIBERVANT?
  • What is Average Wholesale Price for LIBERVANT?
Summary for LIBERVANT
International Patents:20
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Patent Applications: 4,156
What excipients (inactive ingredients) are in LIBERVANT?LIBERVANT excipients list
DailyMed Link:LIBERVANT at DailyMed
Drug patent expirations by year for LIBERVANT
Pharmacology for LIBERVANT
Drug ClassBenzodiazepine

US Patents and Regulatory Information for LIBERVANT

LIBERVANT is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting LIBERVANT

Pharmaceutical compositions with enhanced permeation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting LIBERVANT

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aquestive LIBERVANT diazepam FILM;BUCCAL 218623-001 Apr 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aquestive LIBERVANT diazepam FILM;BUCCAL 218623-004 Apr 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aquestive LIBERVANT diazepam FILM;BUCCAL 218623-002 Apr 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aquestive LIBERVANT diazepam FILM;BUCCAL 218623-004 Apr 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LIBERVANT

See the table below for patents covering LIBERVANT around the world.

Country Patent Number Title Estimated Expiration
Brazil 112020005967 composições farmacêuticas com permeação realçada ⤷  Sign Up
Canada 3022797 COMPOSITIONS PHARMACEUTIQUES A PERMEATION AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION) ⤷  Sign Up
Japan 2024012484 増強された透過を有する医薬組成物 ⤷  Sign Up
China 111132670 具有增强的渗透的药物组合物 (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.